Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГОУ «МГМСУ»; 2Клиника головной боли и вегетативных расстройств акад. Александра Вейна, Москва
Список исп. литературыСкрыть список 1. Бондаренко И.И. Опыт использования антиконвульсанта прегабалина в качестве вспомогательного средства у больных парциальной формой эпилепсии с полиморфными приступами. Журн. неврол. психиатр. им. С.С.Корсакова. 2008; 108 (10): 73–4. 2. Бурд С.Г., Крикова Е.В., Бадалян О.Л. и др. Прегабалин в политерапии парциальной эпилепсии. Журн. неврол. психиатр. им. С.С.Корсакова. 2009; 109 (7): 96–8. 3. Данилов А.Б., Давыдов О.С. Нейропатическая боль. М.: Боргес, 2007. 4. Карлов В.А. Эпилепсия у детей и взрослых, женщин и мужчин. М.: Медицина, 2010. 5. Arroyo S, Anhut H, Kugler AR et al. Pregabalin 1008-011 International Study Group. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004; 45 (1): 20–7. 6. Atlas: Epilepsy Care in the World. World Health Organization, 2005; р. 20–7. 7. Beydoun A, Nasreddine W, Atwch S. Efficacy ant tolerability of pregabalin in partial epilepsy. Expert Rev Neurother 2008; 8: 1013–24. 8. Brodie M. Do we need any more antiepileptic drags? Epilepsy Res 2001; 45: 3–6. 9. Cosford ND, Meinke PT, Stauderman KA, Hess SD. Recent advances in the modulation of voltage-gated ion channels for the treatment of epilepsy. Curr Drug Targets CNS Neurol Disord 2002; 1 (1): 81–104. 10. Dooley DJ, Mieske CA, Borosky SA. Inhibition of K+-evoked glutamate release from rat neocortical and hyppocampal slices by gabapentin. Neurosci Lett 2000; 280: 107–10. 11. Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [3H] norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000; 295: 1086–93. 12. Elger CEBrodie MJ, Anhut H et al. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia 2005; 46: 1926–36. 13. Fink K, Dooley DJ, Meder WP et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacol 2002; 42: 229–36. 14. Hauser WA. Incidence and prevalence. In: Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia: Lippincott-Raven Publishers. 1997; p. 47–57. 15. Huppertz HJ, Feuerstein TJ, Schulze Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia 2001; 42 (6): 790–2. 16. Kalviainen R, Khyuppenen J, Koskenkorva P et al. Clinical picture of EPMI-Unverricht-Lundborg disease. Epilepsia 2008; 49: 549–56. 17. Kwan P. Pregabalin: a new drug for epilepsy, neuropathic pain and anxiety. The Hong Kong Medical Diary 2006; 11 (4): 15–6. 18. Kwan P, Brodie M. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314–9. 19. Losezadi D, Hemming K, Marson AG. Pregabalin add-on for drug-rasistant partial epilepsy. Cochrane Database Syst Rev 1: CD005612. 20. Lyrica (pregabalin) Prodact Monograph. Pfizer Global Pharmaceuticals. Australia: Pfizer; 2005. 21. May TW, Rambeck B, Neb R, Jürgens U. Serum concentrations of Pregabalin in patients with epilepsy: the influence of dose, age and comedication. Ther Drug Monitor 2007; 29 (6): 789–94. 22. Meldrum BS, Rogawsky MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007; 4 (1): 18–61. 23. Rogawsky MA, Bazil CW. New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep 2008; 8 (4): 345–52. 24. Ryvlin P, Perucca E, Rheims S. Pregabalin for the managrment of partial epilepsy. Neuropsych Dis Treat 2008; 4 (6): 1211–24. 25. Ryvlin P, Rheims S, Semah F et al. Meta-Analysis of add-on treatment in drug resistant partial epilepsy: a comprehensive study of 41 randomized controlled trials among 10 AEDs. Neurology 2006; 66 (suppl. 2): A36.